Beam Therapeutics (BEAM) Cash from Financing Activities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Cash from Financing Activities data on file, last reported at $96.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $96.6 million, down 79.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $101.3 million (down 78.82% YoY), and the FY2025 annual result was $478.0 million, up 6079.54% from the prior year.
• Cash from Financing Activities rose to $96.6 million in Q1 2026 per BEAM's latest filing, from $1.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $473.4 million in Q1 2025 and troughed at $133000.0 in Q2 2024.
• A 5-year average of $57.1 million and a median of $22.3 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities slumped 99.88% in 2024, then jumped 16240.32% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $32.0 million in 2022, then rose by 5.31% to $33.7 million in 2023, then tumbled by 89.78% to $3.4 million in 2024, then plunged by 45.24% to $1.9 million in 2025, then jumped by 5022.38% to $96.6 million in 2026.
• Business Quant data shows BEAM's Cash from Financing Activities at $96.6 million in Q1 2026, $1.9 million in Q4 2025, and $1.7 million in Q3 2025.